eISSN: 1897-4317
ISSN: 1895-5770
Gastroenterology Review/Przegląd Gastroenterologiczny
Bieżący numer Archiwum Artykuły zaakceptowane O czasopiśmie Bazy indeksacyjne Prenumerata Kontakt Zasady publikacji prac
NOWOŚĆ
Portal dla gastroenterologów!
www.egastroenterologia.pl
SCImago Journal & Country Rank
3/2017
vol. 12
 
Poleć ten artykuł:
Udostępnij:
więcej
 
 
streszczenie artykułu:
Artykuł przeglądowy

Systemic sclerosis and the gastrointestinal tract

Irena Walecka

Data publikacji online: 2017/09/30
Pełna treść artykułu
Pobierz cytowanie
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 


Systemic sclerosis (SSc) is an autoimmunological disease of unknown origin with complex pathogenesis and multiple organ involvement. It is characterised by vascular and immunological abnormalities leading to fibrosis of the skin and internal organs. It is a rather rare disease with a prevalence of around 20 per 100,000. The disease results in heterogeneous clinical findings and different courses. Systemic sclerosis usually begins with the onset of Raynaud’s phenomenon (RP), followed by skin sclerosis and internal organ involvement, although it may appear synchronously with RP. Gastrointestinal involvement is a serious and prevalent complication of SSc, and the oesophagus is the most frequently affected organ. Both limited and diffuse cutaneous SSc involve internal organs, with the involvement of the gastrointestinal tract as a leading cause of morbidity. At present, treatment is mainly symptomatic with no disease-modifying drugs.
referencje:
Szymanska E, Wieczorek M, Lagun Z. Vascular changes in autoimmunological connective tissue diseases. Acta Angiol 2016; 22: 172-6.
Sticherling M. Systemic sclerosis – dermatological aspects. Part 1: Pathogenesis, epidemiology, clinical findings. Prof. Dr. Jan C. Simon, Leipzig (eds). JDDG 2012; 10: 705-16.
Manetti M, Matucii-Cerinic M. The new frontier in systemic sclerosis: from epigenetics to new treatments. Rheumatology 2015; 54: 1757-8.
Mehra S, Walker J, Patterson K, Fritzler MJ. Autoantibodies in systemic sclerosis. Autoimmun Rev 2013; 12: 340-54.
Sobanski V, Dauchet L, Lefèvre G, et al. Prevalence of anti-RNA polymerase III antibodies in systemic sclerosis: new data from a French cohort and a systematic review and meta-analysis: prevalence of anti-RNAP III in SSc. Arthritis Rheumatol 2014; 66: 407-17.
Tay T, Ferdowsi N, Baron M, et al. Measures of disease status in systemic sclerosis: a systematic review. Semin Arthr Rheum 2017; 46: 473-87.
Braun-Moscovici Y, Brun R, Braun M. Systemic sclerosis and the gastrointestinal tract – clinical approach. Rambam Maimonides Med J 2016; 7: e0031.
Steen VD, Medsger TA Jr. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 2000; 43: 2437-44.
Hudson M, Lo E, Lu Y, et al. Cigarette smoking in patients with systemic sclerosis. Arthritis Rheum 2011; 63: 230-8.
Cohen S, Fisher R, Lipshutz W, et al. The pathogenesis of esophageal dysfunction in scleroderma and Raynaud’s disease. J Clin Investig 1972; 51: 2663-8.
Schmeiser T, Saar P, Jin D, et al. Profile of gastrointestinal involvement in patients with systemic sclerosis. Rheumatol Int 2012; 32: 2471-8.
Tiev KP, Cabane J. Digestive tract involvement in systemic sclerosis. Autoimmun Rev 2011; 11: 68-73.
Zuber-Jerger I, Müller A, Kullmann F, et al. Gastrointestinal manifestation of systemic sclerosis: thickening of the upper gastrointestinal wall detected by endoscopic ultrasound is a valid sign. Rheumatology (Oxford) 2010; 49: 368-72.
Nishimagi E, Tochimoto A, Kawaguchi Y, et al. Characteristics of patients with early systemic sclerosis and severe gastrointestinal tract involvement. J Rheumatol 2007; 34: 2050-5.
Attar A. Digestive manifestations in systemic sclerosis. Ann Med Intern 2002; 153: 260-4.
Pogrel MA. Unilateral osteolysis of the mandibular angle and coronoid process in scleroderma. Int J Oral Maxillofac Surg 1988; 17: 155-6.
Raja J, Ng CT, Sujau I, et al. High-resolution oesophageal manometry and 24-hour impedance-pH study in systemic sclerosis patients: association with clinical features, symptoms and severity. Clin Exp Rheumatol 2016; 34 (5 Suppl. 100): 115-21.
Ntoumazios SK, Voulgari PV, Potsis K, et al. Esophageal involvement in scleroderma: gastroesophageal reflux, the common problem. Semin Arthritis Rheum 2006; 36: 173-81.
Marie I, Gourcerol G, Leroi AM, et al. Delayed gastric emptying determined using the 13C-octanoic acid breath test in patients with systemic sclerosis. Arthritis Rheum 2012; 64: 2346-55.
Elkayam O, Oumanski M, Yaron M, Caspi D. Watermelon stomach following and preceding systemic sclerosis. Semin Arthritis Rheum 2000; 30: 127-31.
Hung EW, Mayes MD, Sharif R, et al. Gastric antral vascular ectasia and its clinical correlates in patients with early diffuse systemic sclerosis in the SCOT trial. J Rheumatol 2013; 40: 455-60.
Fynne L, Worsøe J, Gregersen T, et al. Gastrointestinal transit in patients with systemic sclerosis. Scand J Gastroenterol 2011; 46: 1187-93.
Gregersen H, Liao D, Pedersen J, Drewes AM. A new method for evaluation of intestinal muscle contraction properties: studies in normal subjects and in patients with systemic sclerosis. Neurogastroenterol Motil 2007; 19: 11-9.
Valenzuela A, Li S, Becker L, et al. Intestinal pseudo-obstruction in patients with systemic sclerosis: an analysis of the nationwide inpatient sample. Rheumatology (Oxford) 2016; 55: 654-8.
Kaneko M, Sasaki S, Teruya S, et al. Pneumatosis cystoides intestinalis in patients with systemic sclerosis: a case report and review of 39 Japanese cases. Case Rep Gastrointest Med 2016; 2016: 2474515.
Richard N, Hudson M, Gyger G, et al. Clinical correlates of faecal incontinence in systemic sclerosis: identifying therapeutic avenues. Rheumatology 2017; 56: 581-8.
Malandrini A, Selvi E, Villanova M, et al. Autonomic nervous system and smooth muscle cell involvement in systemic sclerosis: ultrastructural study of 3 cases. J Rheumatol 2000; 27: 1203-6.
Steen VD. Targeted therapy for systemic sclerosis. Autoimmun Rev 2006; 5: 122-4.
Frech TM, Khanna D, Maranian P, et al. Probiotics for the treatment of systemic sclerosis-associated gastrointestinal bloating/distention. Clin Exp Rheumatol 2011; 29 (2 Suppl 65): S22-25.
Nikou GC, Toumpanakis C, Katsiari C, et al. Treatment of small intestinal disease in systemic sclerosis with octreotide: a prospective study in seven patients. J Clin Rheumatol 2007; 13: 119-23.
Marie I, Ducrotte P, Antonietti M, et al. Watermelon stomach in systemic sclerosis: its incidence and management. Aliment Pharmacol Ther 2008; 28: 412-21.
Papachristos DA, Nikpour M, Hair C, Stevens WM. Intravenous cyclophosphamide as a therapeutic option for severe refractory gastric antral vascular ectasia in systemic sclerosis. Intern Med J 2015; 45: 1077-81.
Raja J, Nihtyanova SI, Murray CD, et al. Sustained benefit from intravenous immunoglobulin therapy for gastrointestinal involvement in systemic sclerosis. Rheumatology (Oxford) 2016; 55: 115-9.
Burr SK, Alam A, Cohen R, et al. Lack of effect of sacral nerve stimulation for incontinence in patients with systemic sclerosis. Colorectal Dis 2015; 17: 903-7.
© 2018 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe